ECSP13013011A - Triazolopiridinas - Google Patents
TriazolopiridinasInfo
- Publication number
- ECSP13013011A ECSP13013011A ECSP13013011A ECSP13013011A EC SP13013011 A ECSP13013011 A EC SP13013011A EC SP13013011 A ECSP13013011 A EC SP13013011A EC SP13013011 A ECSP13013011 A EC SP13013011A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- preparing
- triazolopiridins
- prophylaxis
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 150000008523 triazolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11163342 | 2011-04-21 | ||
| EP11167872 | 2011-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13013011A true ECSP13013011A (es) | 2013-12-31 |
Family
ID=46124297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13013011 ECSP13013011A (es) | 2011-04-21 | 2013-11-05 | Triazolopiridinas |
Country Status (39)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| WO2013103724A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| EP2872506A1 (en) * | 2012-07-10 | 2015-05-20 | Bayer Pharma Aktiengesellschaft | Method for preparing substituted triazolopyridines |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| JP2016520634A (ja) * | 2013-06-07 | 2016-07-14 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジン |
| WO2014195276A1 (en) * | 2013-06-07 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | Substituted triazolopyridines having activity as mps-1 inhibitors |
| CN105246891A (zh) * | 2013-06-10 | 2016-01-13 | 拜耳制药股份公司 | 用于治疗癌症的新化合物 |
| EA201600003A1 (ru) * | 2013-06-11 | 2016-06-30 | Байер Фарма Акциенгезельшафт | КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА |
| PT3008062T (pt) * | 2013-06-11 | 2017-06-07 | Bayer Pharma AG | Derivados de profármaco de triazolopiridinas substituídas |
| EP2860177A3 (en) | 2013-09-20 | 2015-06-10 | Bayer Intellectual Property GmbH | Synthesis of functionalized arenes |
| CA2981844A1 (en) | 2015-04-17 | 2016-10-20 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| CN109963854B (zh) * | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
| EP3956330A4 (en) | 2019-04-18 | 2023-01-18 | The Johns Hopkins University | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE |
| US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| DE602005010876D1 (de) | 2004-08-17 | 2008-12-18 | Galderma Res & Dev | Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen |
| CA2662074A1 (en) * | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| AR067562A1 (es) * | 2007-07-18 | 2009-10-14 | Novartis Ag | Compuestos heterociclicos inhibidores de kinasa |
| WO2009024824A1 (en) | 2007-08-23 | 2009-02-26 | Astrazeneca Ab | 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders |
| AU2008291075A1 (en) * | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EA201000797A1 (ru) * | 2007-11-27 | 2011-02-28 | Целльзом Лимитид | Аминотриазолы в качестве ингибиторов pi3k |
| JP2012517971A (ja) * | 2009-02-13 | 2012-08-09 | フォーヴィア・ファーマシューティカルズ | キナーゼ阻害薬としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン類 |
| CA2760077A1 (en) | 2009-04-29 | 2010-11-04 | Marcus Koppitz | Substituted imidazoquinoxalines |
| CN102596932A (zh) | 2009-09-04 | 2012-07-18 | 拜耳医药股份有限公司 | 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉 |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
-
2012
- 2012-04-16 CN CN201280030682.XA patent/CN103608350B/zh not_active Expired - Fee Related
- 2012-04-16 MX MX2013012289A patent/MX348783B/es active IP Right Grant
- 2012-04-16 JP JP2014505584A patent/JP5989091B2/ja not_active Expired - Fee Related
- 2012-04-16 AP AP2013007182A patent/AP3491A/xx active
- 2012-04-16 SG SG2013073044A patent/SG194003A1/en unknown
- 2012-04-16 SI SI201230220T patent/SI2699575T1/sl unknown
- 2012-04-16 PL PL12721779T patent/PL2699575T3/pl unknown
- 2012-04-16 MA MA36344A patent/MA35049B1/fr unknown
- 2012-04-16 CA CA2833657A patent/CA2833657A1/en not_active Abandoned
- 2012-04-16 ME MEP-2015-80A patent/ME02143B/me unknown
- 2012-04-16 RS RS20150345A patent/RS54044B1/sr unknown
- 2012-04-16 PT PT127217792T patent/PT2699575E/pt unknown
- 2012-04-16 US US14/113,017 patent/US20140120087A1/en not_active Abandoned
- 2012-04-16 EP EP12721779.2A patent/EP2699575B1/en active Active
- 2012-04-16 HU HUE12721779A patent/HUE025496T2/en unknown
- 2012-04-16 PH PH1/2013/502169A patent/PH12013502169A1/en unknown
- 2012-04-16 AU AU2012244859A patent/AU2012244859B2/en not_active Ceased
- 2012-04-16 HR HRP20150517TT patent/HRP20150517T1/hr unknown
- 2012-04-16 MY MYPI2013701964A patent/MY164939A/en unknown
- 2012-04-16 PE PE2013002378A patent/PE20141351A1/es not_active Application Discontinuation
- 2012-04-16 WO PCT/EP2012/056914 patent/WO2012143329A1/en not_active Ceased
- 2012-04-16 ES ES12721779.2T patent/ES2539265T3/es active Active
- 2012-04-16 KR KR1020137030546A patent/KR20140025470A/ko not_active Ceased
- 2012-04-16 EA EA201301181A patent/EA023766B1/ru not_active IP Right Cessation
- 2012-04-16 DK DK12721779.2T patent/DK2699575T3/da active
- 2012-04-18 SA SA112330466A patent/SA112330466B1/ar unknown
- 2012-04-18 JO JOP/2012/0093A patent/JO3040B1/ar active
- 2012-04-20 TW TW101114259A patent/TWI558703B/zh not_active IP Right Cessation
- 2012-04-20 UY UY0001034034A patent/UY34034A/es not_active Application Discontinuation
- 2012-04-20 AR ARP120101355A patent/AR086191A1/es unknown
-
2013
- 2013-10-03 IL IL228704A patent/IL228704A0/en unknown
- 2013-10-18 GT GT201300254A patent/GT201300254A/es unknown
- 2013-10-21 CL CL2013003044A patent/CL2013003044A1/es unknown
- 2013-10-21 CR CR20130539A patent/CR20130539A/es unknown
- 2013-10-21 DO DO2013000244A patent/DOP2013000244A/es unknown
- 2013-10-21 CO CO13248763A patent/CO6801751A2/es active IP Right Grant
- 2013-11-05 EC ECSP13013011 patent/ECSP13013011A/es unknown
- 2013-11-20 ZA ZA2013/08707A patent/ZA201308707B/en unknown
-
2015
- 2015-06-12 CY CY20151100512T patent/CY1116439T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2014000133A (es) | Triazolopiridinas sustituidas | |
| ECSP13013011A (es) | Triazolopiridinas | |
| ECSP12011935A (es) | Triazolopiridinas | |
| ECSP12012338A (es) | Triazolopiridinas sustituidas | |
| CO2017001035A2 (es) | “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| ECSP14013217A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk. | |
| NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
| CR20160016A (es) | Pirazolpiridinas sustituidas | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| UY35602A (es) | Compuestos nuevos para el tratamiento del cáncer | |
| CL2011003123A1 (es) | Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras. | |
| UY31903A (es) | 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos | |
| CL2011003355A1 (es) | Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras. | |
| CU20130141A7 (es) | Triazolopiridinas | |
| CL2011001916A1 (es) | Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico. |